CMPX Compass Therapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
13:05
Aug 17
seedy19tron Biotech trader, L/S
Shares options positioning net conviction data.
Shares options positioning data showing net conviction based on fund holdings, no directional view.
CMPX
MED
12:56
Aug 17
seedy19tron Biotech trader, L/S
Reports heaviest selling across specialist funds
"Reports net conviction laggards with heaviest genuine selling across specialist funds in Q2 2026, no directional view."
CMPX
MED
12:52
Aug 17
seedy19tron Biotech trader, L/S
Reports most closed positions across funds
"Reports most closed positions across specialist funds in Q2 2026 excluding M&A take-outs, no directional view."
CMPX
MED
12:32
Aug 17
seedy19tron Biotech trader, L/S
Notes Q2 aggregate fund value decrease
Notes the stock saw one of the largest aggregate value decreases across 93 funds in Q2 13F filings.
CMPX
MED
11:57
Aug 17
seedy19tron Biotech trader, L/S
Reports most closed positions by specialist funds
Reports the most closed positions by specialist funds in Q2 2026, excluding M&A takeouts.
CMPX
MED
16:02
Jan 16
CMPX long into Phase 3 BTC data and CRC catalysts
The author argues CMPX is undervalued with a pipeline worth over $4.5B in peak sales, and that recent institutional ownership and sales hires signal management confidence. The key catalyst is the late-March 2026 Phase 3 COMPANION-002 BTC data readout, described as a major binary event, followed by Q4 2026 Phase 2 CRC data and an expected BLA filing for BTC. The author's $66 price target assumes 100% pipeline success, using a 4x sales multiple on fully diluted shares.
CMPX 1ST
HIGH

About CMPX Investor Commentary

Across the available history and selected sources, Buzzberg tracks CMPX (Compass Therapeutics, Inc.) across 2 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 17% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 6 total trade ideas tracked. Latest voices: seedy19tron, u/Cute_Confidence6033.